Skip to Content

Reneo Pharmaceuticals Inc RPHM

Morningstar Rating
$1.67 +0.02 (1.21%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RPHM is trading at a 72% discount.
Price
$1.69
Fair Value
$3.34
Uncertainty
Extreme
1-Star Price
$76.39
5-Star Price
$1.95
Economic Moat
Lsdh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RPHM is a good fit for your portfolio.

Trading Information

Previous Close Price
$1.65
Day Range
$1.661.71
52-Week Range
$0.9810.98
Bid/Ask
$1.67 / $1.80
Market Cap
$55.81 Mil
Volume/Avg
115,223 / 177,471

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
8

Comparables

Valuation

Metric
RPHM
IMVT
PNT
Price/Earnings (Normalized)
11.36
Price/Book Value
0.635.933.12
Price/Sales
5.50
Price/Cash Flow
13.90
Price/Earnings
RPHM
IMVT
PNT

Financial Strength

Metric
RPHM
IMVT
PNT
Quick Ratio
5.6621.569.01
Current Ratio
5.8722.149.14
Interest Coverage
Quick Ratio
RPHM
IMVT
PNT

Profitability

Metric
RPHM
IMVT
PNT
Return on Assets (Normalized)
−60.40%−43.33%20.67%
Return on Equity (Normalized)
−68.46%−47.83%23.56%
Return on Invested Capital (Normalized)
−67.67%−52.69%23.38%
Return on Assets
RPHM
IMVT
PNT
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJnysrlytnyHwqj$554.7 Bil
VRTX
Vertex Pharmaceuticals IncZpyxdrmzHklxpj$102.7 Bil
REGN
Regeneron Pharmaceuticals IncYmshhfmhPxmmhmh$97.8 Bil
MRNA
Moderna IncBsjmdfcbrGdrh$41.3 Bil
ARGX
argenx SE ADRRtrcldkYdhn$22.3 Bil
BNTX
BioNTech SE ADRCvtghdbdcNhqtt$21.0 Bil
ALNY
Alnylam Pharmaceuticals IncNbgxnvtzDnlhjwr$18.2 Bil
BMRN
Biomarin Pharmaceutical IncHhkzznqcCbjkl$15.4 Bil
RPRX
Royalty Pharma PLC Class ADpfphccytLsnbcb$12.5 Bil
INCY
Incyte CorpFgmypzzxPwvrfx$11.6 Bil

Sponsor Center